RxDoctor Payments Data

Benjamin Davis

Medical · Orange, CANPI 1609247477

Payments from drug & device makers

$8,475in general payments, 2019–2025

Across 402 payments — averaging $21.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Boehringer Ingelheim$1K
  • AbbVie$630
  • Lilly USA, LLC$607
  • Merck$473
  • Novo Nordisk$447
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$8,38999%
  • Education$871%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,475 in reported general payments places this provider in the 90th percentile of 2,087 medical providers in California.

See all medical providers in California

Medicare billing

Part B allowed, 2024
$46,720
Medicare patients
209
Services billed
549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban109$107,355
OzempicSemaglutide89$85,262
Trelegy ElliptaFluticasone/Umeclidin/Vilanter99$78,701
OfevNintedanib Esylate12$77,935
JardianceEmpagliflozin47$47,088
CreonLipase/Protease/Amylase15$45,139
JanuviaSitagliptin Phosphate36$35,148
Breo ElliptaFluticasone/Vilanterol51$29,642
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr35$22,898
TrulicityDulaglutide13$20,790
MounjaroTirzepatide20$20,034
FarxigaDapagliflozin Propanediol15$18,623
EntrestoSacubitril/Valsartan11$17,682
MyrbetriqMirabegron13$17,074
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$12,780

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,113$131,241185 claims
Boehringer IngelheimOfev, Jardiance$1,016$125,02359 claims
PfizerEliquis$223$107,355109 claims
Novo NordiskOzempic$447$85,26289 claims
AbbVieCreon, Synthroid$630$48,29464 claims
Lilly USA, LLCTrulicity, Mounjaro$607$40,82333 claims
MerckJanuvia$473$35,14836 claims
AstraZenecaFarxiga, Breztri Aerosphere$324$31,07835 claims
NovartisEntresto$49$17,68211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,087 medical providers in California.

Other medical in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →